DexamethasoneRecent, repeatedEvidence- NCT07933432 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Dexamethasone” · registered Nov 2026
- NCT07910903 · Keymed Biosciences Co.Ltd · Phase 3 · live · comparator · “Dexamethasone” · registered Oct 2026
- NCT07903272 · Johnson & Johnson · Phase 3 · live · comparator · “Dexamethasone” · registered Oct 2026
- NCT07903506 · Gilead Sciences · Phase 3 · live · background · “Dexamethasone” · registered Oct 2026
- NCT07887672 · Gilead Sciences · Phase 3 · live · background · “Dexamethasone” · registered Oct 2026
| AbbVie11% of its industry studiesUS: off-patent, 28 generics marketedEU: Norgine (EMA 2016) | 2352 studies | 2362 studies | background 141 · comparator 22 |
pomalidomideRecent, repeatedEvidence- NCT07933432 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Pomalidomide Capsules” · registered Nov 2026
- NCT07910903 · Keymed Biosciences Co.Ltd · Phase 3 · live · comparator · “Pomalidomide” · registered Oct 2026
- NCT07825064 · Hoffmann-La Roche · Phase 2 · live · background · “Pomalidomide” · registered Sep 2026
- NCT07742215 · Biocad · Phase 3 · live · comparator · “Daratumumab + pomalidomide + dexamethasone” · registered Jul 2026
- NCT07623798 · Innovent Biologics, Inc. · Phase 3 · live · comparator · “Pomalidomide Capsules” · registered May 2026
| Bristol-Myers Squibb49% of its industry studiesUS: off-patent, 10 generics marketedEU: off-patent, 5 generics authorized | 1827 studies | 1934 studies | comparator 17 · background 25 |
daratumumabRecent, repeatedPhase 4 trial recordedEvidence- NCT07933432 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Daratumumab Injection (Subcutaneous Injection)” · registered Nov 2026
- NCT07910903 · Keymed Biosciences Co.Ltd · Phase 3 · live · comparator · “Daratumumab” · registered Oct 2026
- NCT07887672 · Gilead Sciences · Phase 3 · live · background · “Daratumumab” · registered Oct 2026
- NCT07764861 · Innovent Biologics, Inc. · Phase 2 · live · background · “Daratumumab” · registered Aug 2026
- NCT07742215 · Biocad · Phase 3 · live · comparator · “Daratumumab + pomalidomide + dexamethasone” · registered Jul 2026
| Johnson & Johnson64% of its industry studies | 1629 studies | 1832 studies | comparator 20 · background 22 |
LenalidomideRecent, repeatedEvidence- NCT07903272 · Johnson & Johnson · Phase 3 · live · comparator · “Lenalidomide” · registered Oct 2026
- NCT07903506 · Gilead Sciences · Phase 3 · live · background · “Lenalidomide” · registered Oct 2026
- NCT07887672 · Gilead Sciences · Phase 3 · live · background · “Lenalidomide” · registered Oct 2026
- NCT07764861 · Innovent Biologics, Inc. · Phase 2 · live · comparator · “Lenalidomide” · registered Aug 2026
- NCT07735637 · AstraZeneca · Phase 3 · live · background · “Lenalidomide” · registered Jul 2026
| Bristol-Myers Squibb61% of its industry studiesUS: off-patent, 17 generics marketedEU: off-patent, 4 generics authorized | 1218 studies | 1222 studies | background 41 · comparator 6 |
BortezomibRecent, repeatedEvidence- NCT07933432 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Bortezomib for Injection” · registered Nov 2026
- NCT07903506 · Gilead Sciences · Phase 3 · live · background · “Bortezomib” · registered Oct 2026
- NCT07887672 · Gilead Sciences · Phase 3 · live · background · “Bortezomib” · registered Oct 2026
- NCT07764978 · AstraZeneca · Phase 3 · live · background · “Bortezomib” · registered Jul 2026
- NCT07623798 · Innovent Biologics, Inc. · Phase 3 · live · comparator · “Bortezomib for Injection” · registered May 2026
| Johnson & Johnson33% of its industry studiesUS: off-patent, 15 generics marketedEU: off-patent, 3 generics authorized | 1019 studies | 1226 studies | background 45 · comparator 12 |
carfilzomibRecent, repeatedEvidence- NCT07728188 · AbbVie · Phase 3 · live · comparator · “Carfilzomib” · registered Jul 2026
- NCT07555938 · Hoffmann-La Roche · Phase 3 · live · comparator · “Carfilzomib” · registered Apr 2026
- NCT07391657 · AstraZeneca · Phase 3 · live · comparator · “Carfilzomib” · registered Jan 2026
- NCT07227311 · GlaxoSmithKline · Phase 2 · live · background · “Carfilzomib” · registered Nov 2025
- NCT06892522 · AbbVie · Phase 2 · live · background · “Carfilzomib” · registered Mar 2025
| Amgen61% of its industry studiesUS: ONYX PHARMS AMGEN (FDA 2012)EU: Amgen (EMA 2015) | 913 studies | 1014 studies | comparator 6 · background 18 |
CyclophosphamideRecent, repeatedEvidence- NCT07903506 · Gilead Sciences · Phase 3 · live · background · “Cyclophosphamide” · registered Oct 2026
- NCT07887672 · Gilead Sciences · Phase 3 · live · background · “Cyclophosphamide” · registered Oct 2026
- NCT07735637 · AstraZeneca · Phase 3 · live · background · “Cyclophosphamide” · registered Jul 2026
- NCT07764978 · AstraZeneca · Phase 3 · live · background · “Cyclophosphamide” · registered Jul 2026
- NCT07149857 · Johnson & Johnson · Phase 2 · live · background · “Cyclophosphamide” · registered Aug 2025
| Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed | 510 studies | 511 studies | background 19 |
fludarabineRecent, repeatedPhase 4 trial recordedEvidence- NCT07903506 · Gilead Sciences · Phase 3 · live · background · “Fludarabine” · registered Oct 2026
- NCT07887672 · Gilead Sciences · Phase 3 · live · background · “Fludarabine” · registered Oct 2026
- NCT07735637 · AstraZeneca · Phase 3 · live · background · “Fludarabine” · registered Jul 2026
- NCT07764978 · AstraZeneca · Phase 3 · live · background · “Fludarabine” · registered Jul 2026
- NCT06615479 · Bristol-Myers Squibb · Phase 3 · live · background · “Fludarabine” · registered Sep 2024
| Beijing Biotech18% of its industry studies | 59 studies | 510 studies | background 11 |
elotuzumabRecent, repeatedEvidence- NCT07772024 · CellCentric Ltd. · Phase 3 · live · standard-care · “Investigator's choice of SAT” · registered Aug 2026
- NCT07555938 · Hoffmann-La Roche · Phase 3 · live · comparator · “Elotuzumab” · registered Apr 2026
- NCT06208150 · Johnson & Johnson · Phase 3 · live · comparator · “Elotuzumab” · registered Jan 2024
- NCT06152575 · Pfizer · Phase 3 · live · comparator · “Elotuzumab” · registered Nov 2023
- NCT05730036 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Elotuzumab” · registered Feb 2023
| Bristol-Myers Squibb72% of its industry studiesUS: Bristol-Myers Squibb (FDA 2015)EU: Bristol-Myers Squibb (EMA 2016) | 55 studies | 55 studies | comparator 4 · standard-care 1 |
isatuximabRecent, repeatedEvidence- NCT07903506 · Gilead Sciences · Phase 3 · live · background · “Isatuximab” · registered Oct 2026
- NCT07764978 · AstraZeneca · Phase 3 · live · background · “Isatuximab” · registered Jul 2026
- NCT06119685 · Indapta Therapeutics, INC. · Phase 2 · live · background · “Isatuximab” · registered Oct 2023
- NCT04126200 · GlaxoSmithKline · Phase 2 · live · background · “Isatuximab” · registered Oct 2019
- NCT03989414 · Bristol-Myers Squibb · Phase 2 · live · background · “Isatuximab” · registered Jun 2019
| Sanofi91% of its industry studiesUS: Sanofi (FDA 2020)EU: Sanofi (EMA 2020) | 33 studies | 55 studies | background 5 |
MelphalanRecent, repeatedPhase 4 trial recordedEvidence- NCT07903506 · Gilead Sciences · Phase 3 · live · comparator · “Melphalan” · registered Oct 2026
- NCT07735637 · AstraZeneca · Phase 3 · live · comparator · “Melphalan (part of ASCT)” · registered Jul 2026
- NCT03412565 · Johnson & Johnson · Phase 2 · background · “Melphalan” · registered Jan 2018
- NCT03217812 · Johnson & Johnson · Phase 3 · background · “Melphalan” · registered Jul 2017
- NCT02195479 · Johnson & Johnson · Phase 3 · background · “Melphalan” · registered Jul 2014
| Delcath Systems Inc.33% of its industry studies | 22 studies | 22 studies | comparator 3 · background 10 |
Daratumumab and Hyaluronidase-fihjRecent, repeatedEvidence- NCT06952478 · celltrion · Phase 3 · live · comparator · “Darzalex Faspro(Daratumumab)” · registered Apr 2025
- NCT06742138 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “DARZALEX FASPRO®” · registered Dec 2024
- NCT04776018 · Takeda · Phase 2 · background · “Daratumumab and Hyaluronidase-fihj” · registered Feb 2021
| Johnson & Johnson100% of its industry studies | 22 studies | 22 studies | comparator 2 · background 1 |
selinexorRecent, repeatedEvidence- NCT07623798 · Innovent Biologics, Inc. · Phase 3 · live · comparator · “Selinexor Tablets” · registered May 2026
- NCT07569757 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Selinexor tablets” · registered Apr 2026
| Karyopharm Therapeutics Inc78% of its industry studiesUS: Karyopharm Therapeutics Inc (FDA 2019)EU: Menarini Group (EMA 2021) | 22 studies | 22 studies | comparator 2 |